drugset / Trial / NCT05813587
To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial was a randomized, double-blind, placebo-controlled, loading phase III clinical study.
Timeline
- Start
- 2023-03-23
- Primary completion
- 2023-09-14
- Completion
- 2023-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Meplazumab | Monoclonal antibody | 0.2 mg/kg | Intravenous |